Non‐bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real‐life study

Helicobacter pylori Infection

(2019) Sheila E. Crowe   NEW ENGLAND JOURNAL OF MEDICINE

Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics

(2019) Carlo A. Fallone et al.   GASTROENTEROLOGY

Optimal duration of concomitant nonbismuth quadruple therapy as first-line therapy for Helicobacter pylori

(2019) Christina Kapizioni et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study

(2018) Vincenzo De Francesco et al.   DIGESTIVE AND LIVER DISEASE

The “three-in-one” formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice

(2018) Rocco Maurizio Zagari et al.   HELICOBACTER

Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010–2016

(2018) Giulia Fiorini et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Helicobacter pylori and extragastric diseases: A review

(2018) Antonietta Gerarda Gravina et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial

(2018) Fernando Macías-García et al.   HELICOBACTER

Treatment of Helicobacter pylori infection: A clinical practice update

(2017) Rocco Maurizio Zagari et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment ofHelicobacter pyloriinfection

(2017) Sung Min Park et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

(2016) Carlo A. Fallone et al.   GASTROENTEROLOGY

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

(2016) Jyh-Ming Liou et al.   LANCET

Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015

(2015) Rocco Maurizio Zagari et al.   DIGESTIVE AND LIVER DISEASE

Su1172 Non-Bismuth Quadruple (Concomitant) Therapy for Eradication of H. pylori: Standard vs. Optimized (14-Day, High-Dose PPI) Regimen

(2014) Javier P. Gisbert et al.   GASTROENTEROLOGY

Epidemiology ofHelicobacter pyloriInfection

(2014) Leonardo H. Eusebi et al.   HELICOBACTER

Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance

(2013) Javier Molina–Infante et al.   GASTROENTEROLOGY

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

(2011) Peter Malfertheiner et al.   LANCET